CNTB News and Press, Connect Biopharma Holdings Limited From 05/17/22

SAN DIEGO, CA and TAICANG, China, May 17, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflamma...

OrbiMed Asia V plans to raise $1.1 billion, OrbiMed Flagship IX seeks $1.9 billion and OrbiMed Royalty & Credit Opportunities $1.75 billion. Shanghai Jemincare Pharmaceuticals out-licensed global rights (ex-China) for a novel pain medication to Orion Corporation, a Finnish pharmac...

ArcelorMittal S.A. (NYSE:MT) is scheduled to announce Q1 earnings results on Thursday, May 5th, before market open. The consensus EPS Estimate is $3.41 (+76.7% Y/Y) and the consensus Revenue Estimate is $20.83B (+28.7% Y/Y). Over the last 1 year, MT has beaten EPS estimates 75% of the time an...

Gainers: Sharps Technology (STSS) +43%. TransMedics Group (TMDX) +30%. Super Micro Computer (SMCI) +25%. CarParts.com (PRTS) +25%. Superior Industries International (SUP) +22%. Livent (LTHM) +23%. Bright Health Group (BHG) +21%. eHealth (EHTH) +19%. BlueLinx Holdings (BXC) +18%. Kimball Inter...

Gainers: Bright Health Group BHG +21%. TransMedics Group TMDX +21%. Belite Bio (BLTE) +11%. Sharps Technology STSS +11%. Immutep (IMMP) +7%. Losers: Connect Biopharma CNTB -45%. Amarin AMRN -43%. Kezar Life Sciences (KZR) -35%. MacroGenic...

Connect Biopharma (NASDAQ:CNTB) is trading ~36% lower in the pre-market Wednesday after the clinical-stage biotech announced that its oral ulcerative colitis candidate CBP-307 did not meet the primary endpoint with statistical significance in a mid-stage trial. The 145-patient trial...

Primary endpoint of change from baseline on adapted Mayo Score for CBP-307 0.2 mg once-daily, orally administered dose showed a numerical improvement , but did not achieve statistical significance Clinical Remission on adapted Mayo Score and other secondary endpoints...

Connect Biopharma press release (NASDAQ:CNTB): FY GAAP EPS of -$3.90. Cash and cash equivalents were $267.7M as of December 31, 2021. For further details see: Connect Biopharma GAAP EPS of -$3.90

- Global Phase 3 Trial of CBP-201 in Moderate-to-Severe Atopic Dermatitis Expected to Commence in H2 2022 - - Topline P ha se 2 CBP-307 Results in Mo d er a te-to- S evere Ulcerative Colitis Expected to Be Reported in H1 2022 - - C ...

Gainers: NeuroSense (NRSN) +333%. BitNile (NILE) +69%. Yumanity Therapeutics (YMTX) +50%. BT Brands (BTBD) +41%. Mullen Automotive (MULN) +39%. Hudson Capital (HUSN) +38%. O2Micro International (OIIM) +32%. Cenntro Electric Group (CENN) +33%. Akanda (AKAN) +29%. Anaplan (PLAN) +28%. Losers: V...